Physician profile
Arnaldo E Negron
NPI 1659488138
$4,257.16
in general payments reported to CMS, 2019-2025
31 companies · $752 in 2025
The $752 reported for 2025 was more than what 77% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,559 · 2020: $383 · 2021: $239 · 2022: $330 · 2023: $415 · 2024: $579 · 2025: $752.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,734 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,733.72 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $628.44 | 2019-2025 | Rexulti, Nuedexta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $457.37 | 2022-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $446.72 | 2019-2025 | Trintellix |
| Allergan, INC. | $327.37 | 2019-2020 | |
| Lundbeck LLC | $296.42 | 2019-2025 | Rexulti |
| Axsome Therapeutics, INC. | $280.26 | 2023-2025 | Auvelity, Sunosi |
| Neos Therapeutics, LP | $240.97 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $177.91 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $175.33 | 2019-2025 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $145.86 | 2022-2025 | Austedo, Austedo Xr, Austedo Xr |
| Abbvie INC. | $133.04 | 2021-2025 | |
| Novo Nordisk INC | $117.31 | 2019-2025 | Wegovy, Saxenda |
| Corium, LLC | $100.81 | 2022-2025 | Azstarys |
| Neurocrine Biosciences, INC. | $91.29 | 2019-2025 | |
| Ironshore Pharmaceuticals INC. | $67.99 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $65.04 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $64.42 | 2019-2020 | |
| Alkermes, INC. | $61.42 | 2023-2025 | Aristada, Lybalvi |
| Jazz Pharmaceuticals INC. | $58.65 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $56.06 | 2022-2024 | Qelbree, Qelbree |
| Noven Therapeutics, LLC | $49.68 | 2024 | Xelstrym |
| Bausch Health US, LLC | $46.93 | 2019-2025 | Wellbutrin |
| E.R. Squibb & Sons, L.L.C. | $31.97 | 2025 | Cobenfy |
| Neuronetics, INC. | $23.96 | 2019-2020 | |
| Shire North American Group INC | $23.25 | 2019 | |
| Indivior INC. | $22.65 | 2019 | |
| Idorsia Pharmaceuticals US INC | $14.88 | 2023 | Quviviq |
| Arbor Pharmaceuticals, INC. | $14.44 | 2019 | |
| Merck Sharp & Dohme LLC | $12.64 | 2019 | |
| Adlon Therapeutics L.P. | $12.54 | 2019 | |
| Pernix Therapeutics Holdings, INC. | $11.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arnaldo Negron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.